Medical devices

Medical devices

Until the application of a new regulatory framework for the EU beginning from 26 May 2021, the regulatory framework in the EU for medical devices, active implantable medical devices (AIMDs), and in vitro diagnostic medical devices (IVDs) consisted of:

  1. Directive 93/42/EEC on medical devices

  2. Directive 90/385/EEC on active implantable medical devices

  3. Directive 98/79/EC on in vitro diagnostic medical devices

These MD Directives remain relevant to ‘legacy’ devices and those that were placed on the market before applicable deadlines for certain devices to transition to the new EU regulations. However, all devices must comply with certain increased obligations of compliance under the new EU medical devices regulatory regime. See Practice Note: An introduction to the regulation of medical devices—EU Directives regime.

In the UK, the MD Directives have been implemented via the Medical Devices Regulations 2002 (MDR 2002), SI 2002/618, which were issued under the Consumer Protection Act 1987. The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK competent authority responsible for supervision of medical device regulation. The end of the Brexit transition period

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—4 September 2025

This week’s edition of Life Sciences weekly highlights includes a Law360 news analysis on the Patents Court striking out Sandoz’s claim for an account of profits made from selling blood-thinning treatment Xarelto during an interim sales ban against Bayer and news that the Patents Court addressed cost and interim payments following patent litigation in a complex dispute involving diabetes treatment dapagliflozin. Also included is news that the European Economic and Social Committee (EESC) published its opinion on the proposed EU Critical Medicines Act and Medicines for Europe responded to the European Parliament’s draft report on the Act, highlighting areas of concern, the Commission opened a consultation on revised Good Manufacturing Practice (GMP) quality system guidelines, the MHRA published an update to its March 2025 government response on statutory fees following post-market surveillance legislation for medical devices and published revised guidance on clinical investigations for medical devices, MedTech Europe published a position paper on aligning EU digital legislation with sector-specific frameworks and responded to the Commission’s consultation on extending the Carbon Border Adjustment Mechanism (CBAM). Further news included is that the ABPI announced that the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) scheme review negotiations with the UK government have ended without agreement, the EESC issued its opinion on the EU’s cybersecurity action plan for healthcare, the HRA published a report on the legal and ethical use of patient information in research, the Prescription Medicines Code of Practice Authority (PMCPA) updated guidance on Clauses 3.1 and 11 of the ABPI Code of Practice, which prohibit the promotion of medicines prior to marketing authorisation, among other stories.

View Life Sciences by content type :

Popular documents